Medical device company FlowCardia has announced the completion of enrollment into its U.S. peripheral approach to recanalization in occluded totals (PATRIOT) study, which includes eight hospitals and 85 patients and is designed to assess the safety and efficacy of its line of Crosser catheters in lower limb chronic total occlusions (CTOs).

According to the Sunnyvale, Calif.-based FlowCardia, the Crosser is a rapid exchange catheter delivered over standard .014-inch and .018-inch guidewires to the site of a CTO.